Navigation auf uzh.ch
Navigation auf uzh.ch
Cells that experience stress such as occurring in cancer or inflammatory diseases use various signals to induce a stress response and communicate the stress levels to other cells in the body. One of those signals is a protein modification called ADP-ribosylation. Knowing the precise position and function of ADP-ribosylation on proteins allows the development of new diagnostic and therapeutic tools in various diseases including cancer, infections and neurodegenerative diseases.
First view on extracellular ADP-ribosylation using an advanced mass spectrometry method
This week, researchers from the Department of Molecular Mechanisms of Disease (DMMD) at the University of Zurich (UZH) published in the journal Cell Reports the first description of the extracellular ADP-ribosylomes from cells and tissues, i.e. all proteins carrying the ADP-ribosylation modification and the precise modification site(s) on the proteins.
The researcher focused their analysis on cells of muscle tissue as it has been previously described that an enzyme, called ARTC1, that generates exclusively extracellular ADP-ribosylation is prominently expressed in our skeletal and heart muscle. “Surprisingly, we found that already unstressed cells and tissues comprise a substantial extracellular ADP-ribosylome, which is in contrast to our previous findings on intracellular ADP-ribosylation”, says Dr. Mario Leutert, the first author of the publication, and continues: “Furthermore, it was striking to learn that the ADP-ribosylation sites of muscle and heart are almost exclusively generated by this one enzyme, ARTC1”. These findings had been corroborated in collaboration with a research group from Hamburg led by Prof. Friedrich Koch-Nolte.
“In this study, we also provide evidence for a functional role of extracellular ADP-ribosylation”, says Prof. Michael Hottiger, senior author on the publication and director of the DMMD. Hemopexin is one of the strongest binders of the oxygen-binding molecule hem in the blood and the authors found that ADP-ribosylation of hemopexin reduces its hem-binding capacity. Thus, among many other functions, ADP-ribosylation may regulate hem availability and transport.
Altered ADP-ribosylation status may be a sign of disease
Why is this study important? Prof. Hottiger answers: “With this study we do not just present another method to study proteins and their modification. Together with our previous work and that from other groups in the field, our new results and technical capabilities provide the basis for the future investigations of ADP-ribosylation and its medical implications”. Although ADP-ribosylation is known as a biological process already for 60 years, the functional role of it is still largely unknown, which is due to hitherto lack of appropriate research tools. Still, there is already strong medical evidence that ADP-ribosylation is involved in pathogenic processes and that inhibitors of intracellular ADP-ribosylation, so called PARP inhibitors, are useful in treating cancers such as breast and ovary cancer and may be beneficial in inflammatory conditions.
New diagnostic and therapeutic opportunities
Being now able to study all potential ADP-ribosylated proteins in biopsies or blood at once allows studying the dynamics of ADP-ribosylation at individual protein positions in health and disease. “During the last two years, we have prepared ourselves for this moment and, in parallel, developed the first in kind antibody directed to single-modified, so called mono-ADP-ribosylated proteins” elucidates Prof. Hottiger. “In collaboration with the University Hospital of Zurich, we obtained the first evidence that such antibodies against mono-ADP-ribosylation may be very useful as prognostic tools in certain cancer types”. Prof. Hottiger’s group is now in the process of developing modification- and protein-specific monoclonal antibodies that will allow the determination of the ADP-ribosylation status of a particular protein. In addition, they want to address whether such antibodies would have a therapeutic potential for instance in cancer.
“There is a huge, still undiscovered landscape out there”, concludes Prof. Hottiger, “we still need to learn a lot about ADP-ribosylation, but we are kind of convinced that the medical implications and benefits for patients might be enormous.”
https://www.cell.com/cell-reports/fulltext/S2211-1247(18)31151-3
Proteomic Characterization of the Heart and Skeletal Muscle Reveals Widespread Arginine ADP-Ribosylation by the ARTC1 Ectoenzyme.
Mario Leutert, Stephan Menzel, Rickmer Braren, Björn Rissiek, Ann-Katrin Hopp, Kathrin Nowak, Lavinia Bisceglie, Peter Gehrig, Hui Li, Anna Zolkiewska, Friedrich Koch-Nolte, Michael O. Hottiger
Cell Reports 24(7):1916-1929
Tobias Suter
